Your browser doesn't support javascript.
Risk of death in individuals hospitalized for COVID-19 with and without psychiatric disorders: an observational multicenter study in France.
Hoertel, Nicolas; Sánchez-Rico, Marina; Muela, Pedro de la; Abellán, Miriam; Blanco, Carlos; Leboyer, Marion; Cougoule, Céline; Gulbins, Erich; Kornhuber, Johannes; Carpinteiro, Alexander; Becker, Katrin Anne; Vernet, Raphaël; Beeker, Nathanaël; Neuraz, Antoine; Alvarado, Jesús M; Herrera-Morueco, Juan José; Airagnes, Guillaume; Lemogne, Cédric; Limosin, Frédéric.
  • Hoertel N; AP-HP.Centre, DMU Psychiatrie et Addictologie, Corentin Celton Hospital, Issy-les-Moulineaux, France.
  • Sánchez-Rico M; INSERM U1266, Paris, France.
  • Muela P; Université de Paris, Paris, France.
  • Abellán M; AP-HP.Centre, DMU Psychiatrie et Addictologie, Corentin Celton Hospital, Issy-les-Moulineaux, France.
  • Blanco C; Universidad Complutense de Madrid, Department of Psychobiology & Behavioural Sciences Methods, Faculty of Psychology, Campus de Somosaguas, Pozuelo de Alarcón, Spain.
  • Leboyer M; AP-HP.Centre, DMU Psychiatrie et Addictologie, Corentin Celton Hospital, Issy-les-Moulineaux, France.
  • Cougoule C; Universidad Complutense de Madrid, Department of Psychobiology & Behavioural Sciences Methods, Faculty of Psychology, Campus de Somosaguas, Pozuelo de Alarcón, Spain.
  • Gulbins E; AP-HP.Centre, DMU Psychiatrie et Addictologie, Corentin Celton Hospital, Issy-les-Moulineaux, France.
  • Kornhuber J; Universidad Complutense de Madrid, Department of Psychobiology & Behavioural Sciences Methods, Faculty of Psychology, Campus de Somosaguas, Pozuelo de Alarcón, Spain.
  • Carpinteiro A; Division of Epidemiology, Services and Prevention Research, National Institute on Drug Abuse.
  • Becker KA; AP-HP, DMU IMPACT, Département Médical Universitaire de Psychiatrie, Hôpitaux Universitaires Henri Mondor, Créteil, France.
  • Vernet R; Institut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, Toulouse, France.
  • Beeker N; Institut de Pharmacologie et de Biologie Structurale, IPBS, Université de Toulouse, Toulouse, France.
  • Neuraz A; Department of Molecular Biology, University Medicine Essen, University of Duisburg-Essen, Essen, Germany.
  • Alvarado JM; Department of Psychiatry and Psychotherapy, University Hospital, Friedrich-Alexander-University of Erlangen-Nuremberg, Erlangen, Germany.
  • Herrera-Morueco JJ; Department of Molecular Biology, University Medicine Essen, University of Duisburg-Essen, Essen, Germany.
  • Airagnes G; Department of Hematology and Stem Cell Transplantation, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Lemogne C; Department of Molecular Biology, University Medicine Essen, University of Duisburg-Essen, Essen, Germany.
  • Limosin F; AP-HP.Centre-Université de Paris, Hôpital Européen Georges Pompidou, Medical Informatics, Biostatistics and Public Health Department, Paris.
Biol Psychiatry Glob Open Sci ; 2022 Jan 04.
Article in English | MEDLINE | ID: covidwho-2263016
ABSTRACT

BACKGROUND:

Prior research suggests that psychiatric disorders could be linked to increased mortality among patients with COVID-19. However, whether all or specific psychiatric disorders are intrinsic risk factors of death in COVID-19, or whether these associations reflect the greater prevalence of medical risk factors in people with psychiatric disorders, has yet to be evaluated.

METHODS:

We performed an observational multicenter retrospective cohort study to examine the association between psychiatric disorders and mortality among patients hospitalized for laboratory-confirmed COVID-19 at 36 Greater Paris University hospitals.

RESULTS:

Of 15,168 adult patients, 857 (5.7%) had an ICD-10 diagnosis of psychiatric disorder. Over a mean follow-up of 14.6 days (SD=17.9), death occurred in 326/857 (38.0%) patients with a diagnosis of psychiatric disorder versus 1,276/14,311 (8.9%) in patients without such a diagnosis (OR=6.27; 95%CI=5.40-7.28; p<0.01). When adjusting for age, sex, hospital, current smoking status, and medications according to compassionate use or as part of a clinical trial, this association remained significant (AOR=3.27; 95%CI=2.78-3.85; p<0.01). However, additional adjustments for obesity and number of medical conditions resulted in a non-significant association (AOR=1.02; 95%CI=0.84-1.23; p=0.86). Exploratory analyses following the same adjustments suggest that a diagnosis of mood disorders was significantly associated with reduced mortality, which might be explained by the use of antidepressants.

CONCLUSIONS:

These findings suggest that the increased risk of COVID-19-related mortality in individuals with psychiatric disorders hospitalized for COVID-19 might be explained by the greater number of medical conditions and the higher prevalence of obesity in this population, but not by the underlying psychiatric disease.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Year: 2022 Document Type: Article Affiliation country: J.bpsgos.2021.12.007

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Language: English Year: 2022 Document Type: Article Affiliation country: J.bpsgos.2021.12.007